Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19

Mohamad Y Khatib; Karimulla S Shaik; Amna A Ahmed; Mohammad A Alwraidat; Ahmed S Mohamed; Mohamad R Abou Kamar; Mouhammad Z Sharaf Eldean; Bashar K Aldaraiseh; Abdulqadir J Nashwan

doi:10.1002/ccr3.3487

Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19

Clin Case Rep. 2020 Nov 12;9(1):148-152. doi: 10.1002/ccr3.3487. eCollection 2021 Jan.

Authors

Mohamad Y Khatib¹, Karimulla S Shaik¹, Amna A Ahmed¹, Mohammad A Alwraidat¹, Ahmed S Mohamed¹, Mohamad R Abou Kamar², Mouhammad Z Sharaf Eldean³, Bashar K Aldaraiseh³, Abdulqadir J Nashwan¹

Affiliations

¹ Critical Care Unit Hazm Mebaireek General Hospital (HMGH) Hamad Medical Corporation (HMC) Doha Qatar.
² Department of Infectious Diseases Communicable Disease Center (CDC) Hamad Medical Corporation (HMC) Doha Qatar.
³ Department of Laboratory Medicine and Pathology (DLMP) Hamad Medical Corporation (HMC) Doha Qatar.

Abstract

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.

Keywords: COVID‐19; cytomegalovirus colitis; double‐barrel colostomy; lower gastrointestinal bleeding; tocilizumab.

Publication types

Case Reports